Simba Gill, PhD
Executive Chair
We’re lucky to have Simba’s unmatched energy and depth—four decades of biotech leadership distilled into clear vision, unshakable optimism, and the kind of passion that lifts everyone around him.
Sensorium embraces and decodes the complexities of human biology and nature to develop breakthrough medicines for people suffering from brain and mental health conditions.
Sensorium embraces and decodes the complexities of human biology and nature to develop breakthrough medicines for people suffering from brain and mental health conditions.
Leveraging millennia of human insight and cutting edge AI, we’re re-engineering molecules that co‑evolved with people to advance mental & brain health.
We begin with bio‑actives that history already proved compatible with human biology.
Neuroscientists and chemists triage signals from ethnobotany, clinic, and omics.
Graph learning connects hidden compound‑target links; generative models propose optimized analogs.
Our discovery platform SensAI™ holistically integrates comprehensive biological data to identify compounds with a high probability of clinical success.
Social anxiety disorder
SENS-01
Clinical candidate
Drug-resistant epilepsy + anxiety
SENS–03
Lead candidate
Social anxiety disorder
SENS–01
Clinical candidate
Drug-resistant epilepsy + anxiety
SENS–03
Lead candidate
Sensorium is led by executives and advisors with a record of innovation, a drive to explore, and a vision for mental health evolution.
Sensorium Therapeutics is a preclinical biotechnology company developing mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class treatment for anxiety—and built a robust IP estate extending into the 2040s.
© 2025 Sensorium Therapeutics.
All rights reserved.
FCOI policy
Privacy policy